X4 Pharmaceuticals, Inc. (XFOR) financial statements and ratios from SEC XBRL: revenue $6.50M (TTM), net margin -1218.4%, revenue growth 154.2% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $6.50M |
| Net Margin | -1218.4% |
| Revenue Growth (YoY) | 154.2% |
| EPS Growth (YoY) | 884.2% |
| FCF Growth (YoY) | -34.8% |
| Price / Book | 2.26 |
| Price / Sales | 56.65 |
| FCF Yield | -32.8% |
| Altman Z-Score | -0.75 (distress) |
| Piotroski F-Score | 4/9 |
| Sector P/E (Healthcare) | 21.7 |
XFOR overview · XFOR earnings · XFOR KPIs · XFOR investor relations · XFOR ownership · XFOR peers · XFOR filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.